Abnormal gene splicing in neuropathic pain - Supplement
神经性疼痛中的异常基因剪接 - 补充
基本信息
- 批准号:10404737
- 负责人:
- 金额:$ 9.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2022-01-02
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAcuteAlternative SplicingAnalgesicsAnimal ModelAreaBehavioralBioinformaticsCalcium ChannelCellsChIP-seqComplementComputer AnalysisDNA Modification ProcessData SetDevelopmentDiseaseElectrophysiology (science)EnvironmentEpigenetic ProcessEventExonsFunctional disorderGene AbnormalityGene ExpressionGenesGenomic DNAGoalsGrantGrowth and Development functionInternationalLeadMentorsModificationMolecularMolecular and Cellular BiologyMorphineNeuronsNociceptorsPainPathologicPeripheral nerve injuryProtein IsoformsRNA SplicingResearchResearch PersonnelResolutionScientistSpinal GangliaSpinal cord posterior hornSpliced GenesTechniquesTherapeuticTrainingTranscriptUniversitiesaddictionbisulfite sequencingcareercareer developmentchronic painexperimental studygenome-wideinhibitor/antagonistlarge datasetsmRNA Precursornerve damagenerve injuryneurotransmitter releasenovel therapeuticspainful neuropathypatch clamppublic health prioritiestherapeutic effectivenesstherapeutic targettranscriptometranscriptome sequencingvoltagewhole genome
项目摘要
PROJECT SUMMARY ABSTRACT
Alternative splicing of the Cacna1b gene generates a number of functionally different voltage gated CaV2.2
calcium channel isoforms. CaV2.2 controls neurotransmitter release at nociceptor terminals in the dorsal horn of
the spinal cord and is a key therapeutic target of analgesics used to treat neuropathic pain. CaV2.2 inhibitors are
analgesic but their therapeutic effectiveness are complicated by the lack of broad efficacy, narrow therapeutic
window, off target actions and addiction. In nociceptors, cell-specific alternative splicing of CaV2.2 pre-mRNA
generates isoforms that have different sensitivities to morphine. Normal splicing of CaV2.2 is disrupted in
nociceptors following peripheral nerve injury, contributing to the well documented loss of morphine efficacy in
neuropathic pain. In preliminary experiments, the applicant shows that epigenetic modification of genomic DNA
controls the cell-specific expression of an alternatively spliced exon in the Cacna1b gene in nociceptors. This
modification of genomic DNA is altered after nerve injury leading to abnormal alternative splicing. The applicant
proposes that this is a key alteration underlying the pathophysiology of neuropathic pain. In this proposal, he
plans to expand on his studies to identify genome-wide nociceptor-specific alternative splicing events that are
disrupted in an animal model of neuropathic pain. The applicant will generate high-resolution, genome-wide
RNA-seq datasets to identify nociceptor-specific splice isoforms. Additionally, he will determine epigenetic
modifications of DNA that associated with and control alternative splicing. He will further demonstrate how these
are altered in nociceptors after nerve injury applying the techniques of whole genome bisulfite sequencing and
ChIP-seq. He will use these datasets to determine events that lead to aberrant alternative splicing in nociceptors
and, as a consequence, inform strategies to correct deficits in alternative splicing to treat neuropathic pain.
The applicant long-term career goal is to become an independent scientist in academia focusing his research in
how transcriptome-epigenetic interactions drives cell-specific gene expression in neurons and how they are
disrupted in diseases such chronic pain. To achieve these goals, he will undertake extensive training in
bioinformatic and computational analysis of large data sets. This new training will complement his background
in patch-clamp electrophysiology, cellular and molecular biology and behavioral analyses. The Brown University
environment combined with proposed mentors and consultants provides the best path for his scientific growth
and career development. This training grant will allow the applicant to bridge different research areas to
understand cell-specific processing, and be a competitive and interdisciplinary investigator.
项目摘要
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eduardo Javier Lopez Soto其他文献
Eduardo Javier Lopez Soto的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eduardo Javier Lopez Soto', 18)}}的其他基金
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 9.15万 - 项目类别:
Standard Grant














{{item.name}}会员




